Document Detail

Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial.
MedLine Citation:
PMID:  8996417     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Use of aggressive and invasive interventions is more common in the USA than in other countries. We have compared use of resources for patients with cardiogenic shock after myocardial infarction in the USA and in other countries, and assessed the association between use of resources and clinical outcomes. METHODS: We analysed data for patients with cardiogenic shock after myocardial infarction who were enrolled in the GUSTO-I trial (1891 treated in the USA, 1081 treated in other countries). Patients were randomly assigned combinations of streptokinase, heparin, and accelerated tissue-plasminogen activator (t-PA), then decisions about further interventions were left to the discretion of the attending physician. The interventions included in our analysis were: pulmonary-artery catheterisation, cardiac catheterisation, intravenous inotropic agents, ventilatory support, intra-aortic balloon counterpulsation (IABP), percutaneous transluminal coronary angioplasty (PTCA), and coronary bypass graft surgery (CABG). The primary outcome measure was death from any cause at 30 days of follow-up. FINDINGS: Patients who were treated in the USA were significantly younger than those treated elsewhere (median 68 [IQR 59-75] vs 70 [62-76], p < 0.001), a smaller proportion had anterior infarction (49 vs 53%, p < 0.001), and they had a shorter time to treatment (mean 3.1 vs 3.3 h, p < 0.001). Aggressive diagnostic and therapeutic procedures were used more commonly in the USA than in the other countries: cardiac catheterisation (58 vs 23%); IABP (35 vs 7%); right-heart catheterisation (57 vs 22%); and ventilatory support (54 vs 38%). 483 (26%) of the patients treated in the USA underwent PTCA, compared with 82 (8%) patients in other countries. Patients who underwent revascularisation had better survival in all countries. Adjusted 30-day mortality was significantly lower among patients treated in the USA than among those treated elsewhere (50 vs 66%, p < 0.001). The difference in mortality remained at 1 year-56% of patients treated in the USA died versus 70% of patients treated elsewhere (hazard ratio 0.69 [95% CI 0.63-0.75], p < 0.001). INTERPRETATION: 30-day and 1-year mortality was significantly lower among patients treated in the USA than among those treated in other countries. This difference in mortality may be due to the greater use of invasive diagnostic and therapeutic interventions in the USA.
D R Holmes; R M Califf; F Van de Werf; P B Berger; E R Bates; M L Simoons; H D White; T D Thompson; E J Topol
Related Documents :
1135747 - External counterpulsation in low cardiac output states.
16845247 - The initial anion gap is a predictor of mortality in acute myocardial infarction.
16175027 - Myocardial dysfunction in meningococcal septic shock.
17227587 - Skeletal muscle oxygen saturation does not estimate mixed venous oxygen saturation in p...
3289357 - Comparison of intravenous anisoylated plasminogen streptokinase activator complex and i...
23462637 - How to transform peripheral extracorporeal membrane oxygenation in the simplest mid-ter...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Lancet     Volume:  349     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1997 Jan 
Date Detail:
Created Date:  1997-02-06     Completed Date:  1997-02-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  75-8     Citation Subset:  AIM; IM    
Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary
Coronary Artery Bypass
Fibrinolytic Agents / therapeutic use
Health Resources / utilization*
Heart Catheterization
Heparin / therapeutic use
Intra-Aortic Balloon Pumping
Middle Aged
Myocardial Infarction / complications,  mortality*,  therapy*
Plasminogen Activators / therapeutic use
Shock, Cardiogenic / etiology,  therapy*
Streptokinase / therapeutic use
Thrombolytic Therapy
Tissue Plasminogen Activator / therapeutic use
Treatment Outcome
Reg. No./Substance:
0/Fibrinolytic Agents; 9005-49-6/Heparin; EC 3.4.-/Streptokinase; EC 3.4.21.-/Plasminogen Activators; EC Plasminogen Activator
Comment In:
Lancet. 1997 Mar 29;349(9056):951; author reply 952   [PMID:  9093267 ]
Lancet. 1997 Mar 29;349(9056):951-2; author reply 952   [PMID:  9093268 ]
Lancet. 1997 Mar 29;349(9056):951; author reply 952   [PMID:  9093266 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The influence of temocapril, an angiotensin converting enzyme inhibitor, on the cyclosporine-induced...
Next Document:  Progression of ischaemic stroke and excitotoxic aminoacids.